Evidence map›Paper›PMID 40421422›Full record

ArticleBioinformatics advances2025

HIV multidrug class resistance prediction with a time sliding anchor approach.

Nurhan Arslan, Ralf Eggeling, Bernhard Reuter, Kristel Van Leathem, Marta Pingarilho, Perpétua Gomes, Anders Sönnerborg, Rolf Kaiser, Maurizio Zazzi, Nico Pfeifer

Abstract read
In one paragraph

Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nurhan ArslanMethods in Medical Informatics, Department of Computer Science, University of Tuebingen, Tuebingen 72076, Germany.ORCID https://orcid.org/0009-0008-5029-8331
Ralf EggelingMethods in Medical Informatics, Department of Computer Science, University of Tuebingen, Tuebingen 72076, Germany.ORCID https://orcid.org/0000-0002-3583-1029
Bernhard ReuterMethods in Medical Informatics, Department of Computer Science, University of Tuebingen, Tuebingen 72076, Germany.ORCID https://orcid.org/0000-0002-1617-6778
Kristel Van LeathemLaboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven 3000, Belgium.ORCID https://orcid.org/0000-0001-6036-2271
Marta PingarilhoGlobal Health and Tropical Medicine, GHTM, Associate Laboratory in Translation and Innovation towards Global Health, LA-REAL, Instituto de Higiene e Medicina Tropical, IHMT, Universidade NOVA de Lisboa, Lisbon 1349-008, Portugal.ORCID https://orcid.org/0000-0002-7928-3087
Perpétua GomesLaboratório de Biologia Molecular, LMCBM, SPC, Unidade Local de Saúde Lisboa Ocidental, Hospital Egas Moniz, Caparica 2829-511, Portugal.ORCID https://orcid.org/0000-0003-3271-8255
Anders SönnerborgDepartment of Medicine Huddinge, Karolinska University Hospital, Stockholm 14186, Sweden.ORCID https://orcid.org/0000-0001-8928-3374
Rolf KaiserInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne 50935, Germany.ORCID https://orcid.org/0000-0002-2640-2548
Maurizio ZazziDepartment of Medical Biotechnology, University of Siena, Siena 53100, Italy.ORCID https://orcid.org/0000-0002-0344-6281
Nico PfeiferMethods in Medical Informatics, Department of Computer Science, University of Tuebingen, Tuebingen 72076, Germany.ORCID https://orcid.org/0000-0002-4647-8566

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: The emergence of multidrug class resistance (MDR) in Human Immunodeficiency Virus (HIV) is a rare but significant challenge in antiretroviral therapy (ART). MDR, which may arise from prolonged drug exposure, treatment failures, or transmission of resistant strains, accelerates disease progression and poses particular challenges in resource-limited settings with restricted access to resistance testing and advanced therapies. Early prediction of future MDR development is important to inform therapeutic decisions and mitigate its occurrence. Results: In this study, we employ various machine learning classifiers to predict future resistance to all four major antiretroviral drug classes using features extracted from clinical HIV sequence data. We systematically explore several variations of the problem that differ in the pre-existing resistance level and the temporal gap between sample collection and observed MDR occurrence. Our models show the ability to predict multidrug class resistance even in the most challenging variations, albeit at a reduced accuracy. Feature importance analysis reveals that our models primarily utilize known drug resistance mutations for easier classification tasks, but rely on new mutations for the difficult task of distinguishing four class drug resistance from three class drug resistance. Availability and implementation: All analysis was performed using the Euresist Integrated DataBase (EIDB). Researchers wishing to reproduce, validate or extend these findings can request access to the latest EIDB release via the Euresist Network.

Identifiers

PMID40421422
PMCPMC12104520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.